BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Core Points - BioXcel Therapeutics, Inc. has regained compliance with Nasdaq's minimum closing bid price requirement [1][2] - The company was previously notified on September 16, 2024, for failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days [2] - To regain compliance, the company needed to maintain a minimum closing bid price of$1.00 per share for at least 12 consecutive trading days, which was achieved on February 26, 2025 [2] Company Overview - BioXcel Therapeutics, Inc. is a biopharmaceutical company that utilizes artificial intelligence to develop transformative medicines in neuroscience [3] - The company's subsidiary, OnkosXcel Therapeutics, focuses on developing medicines in immuno-oncology [3] - BioXcel employs a drug re-innovation approach, leveraging existing approved drugs and big data with proprietary machine learning algorithms to identify new therapeutic indications [3]